May 14, 2020 Re: Clarification of the operating results of company and its subsidiaries for the three months period end March 31, 2020 To: President The Stock Exchange of Thailand K.C. Property
-TRANSLATION- 15 May 2020 Subject : Management Discussion and Analysis for Q1/2020 Attention : President The Stock Exchange of Thailand An overview of the results in the passing The performance in
นาสูความเปนเลิศ ทั้งในดานพาณิชยและคุณภาพผลิตภัณฑอยางเปนมืออาชพี” May 15, 2020 Subject: Clarification on the cause of changes in operating results. To: Director and Manager The Stock Exchange of
-TRANSLATION- 14 August 2020 Subject : Management Discussion and Analysis for Q2/2020 Attention : President The Stock Exchange of Thailand An overview of the results in the passing The performance in
(Translation) 1/4 November 16, 2020 Re: Clarification of the operating results of company and its subsidiaries for the nine months period end September 30, 2020 To: President The Stock Exchange of
www.interpharma.co.th IP_OCS/010/2562 November 10, 2019 Subject Management’s discussion and analysis for the third quarter of 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited (“the
(Ending September 30, 2019) To Director and Manager of the Stock Exchange of Thailand Ubis (Asia) Public Company Limited (“the Company”) would like to clarify on the performance and the financial for Q3
Page 1 of 3 No. ACC6308/001 August 11, 2021 Subject: Clarification of the operating results quarter 2/2021 of the year ended June 30, 2021 Attention : Director and Managing Director, The Stock
Page 1 of 3 No. ACC6411/003 November 11, 2021 Subject: Clarification of the operating results quarter 3/2021 of the year ended September 30, 2021 Attention : Director and Managing Director, The Stock
? wrongdoings are in contravention of Sections 311 and 315 of the Securities and Exchange Act B.E. 2535 (1992). The SEC investigation stemmed from a referral from the Stock Exchange of Thailand identifying